脓毒症期间肌钙蛋白I水平与脓毒症后心血管并发症的关联
该研究纳入2011至2017年21家医院收治的40岁及以上、5年内无既往心血管病的脓毒症成人,按脓毒症期间峰值肌钙蛋白I分为正常(≤0.04 ng/ml)及三个异常三分位组。14,046例中2,012例(14.3%)在脓毒症后1年发生心血管复合结局,各异常三分位组发生率均高于正常组(P < 0.001)。多因素校正竞争风险模型显示,三个异常三分位组心血管事件风险均升高(aHR分别为1.37、1.44、1.77)。作者认为,脓毒症期间肌钙蛋白升高可识别脓毒症后心血管并发症高风险患者。
要点
- 脓毒症期间峰值肌钙蛋白I >0.04 ng/ml者,脓毒症后1年心血管复合结局风险升高,且随三分位升高而增加(aHR最高1.77)。
- 正常组(≤0.04 ng/ml)复合心血管结局发生率为10.9%,三个异常三分位组分别为17.3%、17.6%、20.3%(P < 0.001)。
- 复合结局包括动脉粥样硬化性心血管病、心房颤动和心力衰竭。
- 适用人群为40岁及以上、5年内无既往心血管病的脓毒症成人。
- 作者认为,对这一高危亚组采取减轻心血管并发症的策略是必要的。
适用人群与场景
- 2011至2017年21家医院收治的脓毒症成人,年龄≥40岁,且5年内无既往心血管病。
- 研究对象为脓毒症期间测量了肌钙蛋白I的成人。
诊断标准与关键阈值
- 峰值肌钙蛋白I正常:≤0.04 ng/ml。
- 峰值肌钙蛋白I异常三分位:>0.04至≤0.09 ng/ml、>0.09至≤0.42 ng/ml、>0.42 ng/ml。
研究设计与关键结果
- 研究类型为多中心队列分析,纳入21家医院2011至2017年收治的14,046例符合条件的脓毒症成人。
- 主要终点为脓毒症后1年心血管复合结局(动脉粥样硬化性心血管病、心房颤动和心力衰竭)。
- 2,012例(14.3%)发生复合心血管结局;正常组832例(10.9%),三个异常三分位组分别为370例(17.3%)、376例(17.6%)、434例(20.3%)(P < 0.001)。
- 以死亡为竞争风险的多因素校正病因特异性Cox模型显示,三个异常三分位组心血管事件风险均升高:aHR 1.37(95%CI 1.20-1.55)、aHR 1.44(95%CI 1.27-1.63)、aHR 1.77(95%CI 1.56-2.00)。
- 模型校正了脓毒症前和脓毒症期间的潜在混杂因素。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对40岁及以上、5年内无既往心血管病的脓毒症成人,脓毒症期间峰值肌钙蛋白I >0.04 ng/ml提示脓毒症后1年心血管并发症风险升高。
- 作者认为,对这一高危亚组采取减轻心血管并发症的策略是必要的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Sepsis commonly results in elevated serum troponin levels and increased risk for postsepsis cardiovascular complications; however, the association between troponin levels during sepsis and cardiovascular complications after sepsis is unclear.Objectives: To evaluate the association between serum troponin levels during sepsis and 1 year after sepsis cardiovascular events.Methods: We analyzed adults aged ⩾40 years without preexisting cardiovascular disease within 5 years, admitted with sepsis across 21 hospitals from 2011 to 2017. Peak serum troponin I levels during sepsis were grouped as normal (⩽0.04 ng/ml) or tertiles of abnormal (>0.04 to ⩽0.09 ng/ml, >0.09 to ⩽0.42 ng/ml, or >0.42 ng/ml). Multivariable adjusted cause-specific Cox proportional hazards models with death as a competing risk were used to assess associations between peak troponin I levels and a composite cardiovascular outcome (atherosclerotic cardiovascular disease, atrial fibrillation, and heart failure) in the year following sepsis. Models were adjusted for presepsis and intrasepsis factors considered potential confounders.Measurements and Main Results: Among 14,046 eligible adults with troponin I measured, 2,012 (14.3%) experienced the composite cardiovascular outcome, including 832 (10.9%) patients with normal troponin levels, as compared with 370 (17.3%), 376 (17.6%), and 434 (20.3%) patients within each sequential abnormal troponin tertile, respectively (P < 0.001). Patients within the elevated troponin tertiles had increased risks of adverse cardiovascular events (adjusted hazard ratio [aHR]troponin0.04-0.09 = 1.37; 95% confidence interval [CI], 1.20-1.55; aHRtroponin0.09-0.42 = 1.44; 95% CI, 1.27-1.63; and aHRtroponin>0.42 = 1.77; 95% CI, 1.56-2.00).Conclusions: Among patients without preexisting cardiovascular disease, troponin elevation during sepsis identified patients at increased risk for postsepsis cardiovascular complications. Strategies to mitigate cardiovascular complications among this high-risk subset of patients are warranted.
参考来源
- Garcia MA, Rucci JM, Thai KK, et al. Association between Troponin I Levels during Sepsis and Postsepsis Cardiovascular Complications. Am J Respir Crit Care Med. 2021. PMID: 34038701. doi:10.1164/rccm.202103-0613OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。